Nektar Therapeutics (NKTR) is a publicly traded Healthcare sector company. As of May 21, 2026, NKTR trades at $69.49 with a market cap of $2.31B and a P/E ratio of -8.33. NKTR moved +2.89% today. Year to date, NKTR is +56.26%; over the trailing twelve months it is +574.24%. Its 52-week range spans $6.48 to $109.00. Analyst consensus is strong buy with an average price target of $153.71. Rallies surfaces NKTR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What do analysts rate NKTR?
9 analysts cover NKTR: 0 strong buy, 8 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $153.71.
Zalevsky Jonathan sold 180 (~$13.14K) on Feb 18, 2026.
ROBIN HOWARD W sold 423 (~$30.88K) on Feb 18, 2026.
Zalevsky Jonathan sold 3.87K (~$137.94K) on Jan 20, 2026.
Common questions about NKTR
What do analysts rate NKTR?
9 analysts cover NKTR: 0 strong buy, 8 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $153.71.
Does Rallies show NKTR price targets?
Yes. Rallies tracks NKTR analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is NKTR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NKTR. It does not provide personalized investment advice.
